Advaxis Inc logo

ADXS - Advaxis Inc Share Price

$0.532 0.0  0.5%

Last Trade - 01/04/20

Sector
Healthcare
Size
Micro Cap
Market Cap £25.7m
Enterprise Value £-1.79m
Revenue £965k
Position in Universe 4696th / 6307
Bullish
Bearish
Unlock ADXS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADXS Revenue Unlock ADXS Revenue

Net Income

ADXS Net Income Unlock ADXS Revenue

Normalised EPS

ADXS Normalised EPS Unlock ADXS Revenue

PE Ratio Range

ADXS PE Ratio Range Unlock ADXS Revenue

Dividend Yield Range

ADXS Dividend Yield Range Unlock ADXS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADXS EPS Forecasts Unlock ADXS Revenue
Profile Summary

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Directors
Last Annual October 31st, 2019
Last Interim January 31st, 2020
Incorporated February 28, 2002
Public Since July 28, 2005
No. of Shareholders: n/a
No. of Employees: 35
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 60,245,793
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADXS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADXS
Upcoming Events for ADXS
Monday 4th May, 2020
Advaxis Inc Annual Shareholders Meeting
Monday 8th June, 2020 Estimate
Q2 2020 Advaxis Inc Earnings Release
Monday 7th September, 2020 Estimate
Q3 2020 Advaxis Inc Earnings Release
Similar to ADXS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.